100 related articles for article (PubMed ID: 23079231)
1. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin.
Deters M; Hütten H; Kaever V
Phytomedicine; 2013 Jan; 20(2):120-3. PubMed ID: 23079231
[TBL] [Abstract][Full Text] [Related]
2. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition.
Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H
Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450
[TBL] [Abstract][Full Text] [Related]
3. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
[TBL] [Abstract][Full Text] [Related]
4. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of curcumin on gastric cancer cells: a proteomic study of molecular targets.
Cai XZ; Huang WY; Qiao Y; Du SY; Chen Y; Chen D; Yu S; Che RC; Liu N; Jiang Y
Phytomedicine; 2013 Apr; 20(6):495-505. PubMed ID: 23351961
[TBL] [Abstract][Full Text] [Related]
6. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
7. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling.
Ranjan D; Chen C; Johnston TD; Jeon H; Nagabhushan M
J Surg Res; 2004 Oct; 121(2):171-7. PubMed ID: 15501456
[TBL] [Abstract][Full Text] [Related]
8. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition.
Wong TF; Takeda T; Li B; Tsuiji K; Kitamura M; Kondo A; Yaegashi N
Gynecol Oncol; 2011 Jul; 122(1):141-8. PubMed ID: 21450334
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
10. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
11. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin.
Einbond LS; Wu HA; Kashiwazaki R; He K; Roller M; Su T; Wang X; Goldsberry S
Fitoterapia; 2012 Oct; 83(7):1160-8. PubMed ID: 22828666
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibition and erythropoiesis: microcytosis or anaemia?
Diekmann F; Rovira J; Diaz-Ricart M; Arellano EM; Vodenik B; Jou JM; Vives-Corrons JL; Escolar G; Campistol JM
Nephrol Dial Transplant; 2012 Feb; 27(2):537-41. PubMed ID: 21785038
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
[TBL] [Abstract][Full Text] [Related]
14. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
[TBL] [Abstract][Full Text] [Related]
15. Effect of immunosuppressive drugs on DNA repair in human peripheral blood mononuclear cells.
Herman-Edelstein M; Rozen-Zvi B; Zingerman B; Lichtenberg S; Malachi T; Gafter U; Ori Y
Biomed Pharmacother; 2012 Mar; 66(2):111-5. PubMed ID: 22244961
[TBL] [Abstract][Full Text] [Related]
16. Effect of different immunosuppressive drugs on immune cells from young and old healthy persons.
Welzl K; Kern G; Mayer G; Weinberger B; Säemann MD; Sturm G; Grubeck-Loebenstein B; Koppelstaetter C
Gerontology; 2014; 60(3):229-38. PubMed ID: 24434865
[TBL] [Abstract][Full Text] [Related]
17. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
19. Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation.
Ranjan D; Johnston TD; Wu G; Elliott L; Bondada S; Nagabhushan M
J Surg Res; 1998 Jul; 77(2):174-8. PubMed ID: 9733605
[TBL] [Abstract][Full Text] [Related]
20. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
